Heterocyclic compounds can be divided into two categories: alicyclic heterocycles and aromatic heterocycles. Compounds whose heterocycles in the molecular skeleton cannot reflect aromaticity are called alicyclic heterocyclic compounds. Compound: 17696-11-6, is researched, Molecular C8H15BrO2, about Aiming at the tumor-specific accumulation of MGMT-inhibitors: First description of a synthetic strategy towards inhibitor-peptide conjugates, the main research direction is peptide benzylguanine conjugate MGMT inhibitor synthesis antitumor agent; drug target tumor adjuvant alkylating therapy; solid phase peptide synthesis Michael reaction conjugation.HPLC of Formula: 17696-11-6.
In the therapy of cancer, alkylating agents are an efficient and often-used substance class. However, cells can repair the resulting alkyl modifications in the O6-position of guanine using the repair protein methylguanine methyltransferase (MGMT), giving rise to resistance and inefficient therapy. A possibility to overcome this resistance is the use of MGMT inhibitors as adjuvants to alkylating therapies. However, MGMT inhibitors also sensitize healthy cells towards alkylating therapies. A strategy to circumvent this is the development of tumor-specific inhibitors which could be based on peptidic ligands as carriers. Such constructs would enable a receptor-specific uptake into tumors. Furthermore, the MGMT inhibitors could be adapted to the resp. tumor entity by changing the peptide carrier. However, no peptide-based tumor-specific MGMT inhibitors were described so far. Thus, we have developed a synthetic strategy to obtain covalent conjugates of receptor-specific peptides and O6-benzylguanine derivatives As model compounds, the MGMT inhibitor O6-(3-bromobenzyl)guanine and the receptor-specific peptides c(RGDfK), TATE, PESIN, neurotensin-2656 and minigastrin-9 were chosen and successfully assembled to obtain potentially tumor-specific MGMT inhibitors. Both, the O6-(3-bromobenzyl)guanine as well as the peptide derivatives are easily replaceable during the syntheses to tailor peptide-based bioconjugates adaptable to the specific tumor entity.
This literature about this compound(17696-11-6)HPLC of Formula: 17696-11-6has given us a lot of inspiration, and I hope that the research on this compound(8-Bromooctanoic acid) can be further advanced. Maybe we can get more compounds in a similar way.
Reference:
Bromide – Wikipedia,
bromide – Wiktionary